HNRNPAB interacted with mRNAs in estrogen receptor positive (ER+) breast cancer [RIP-Seq]

Breast cancer (BC) is the most prevailing type of cancer among women in the world. HNRNPAB belongs to heterogeneous nuclear ribonucleoproteins (hnRNPs) subfamily.In recent years, studies have found that HNRNPAB can be involved in the progression of various human cancers. It not only combines with DNA and RNA, but also mediates mRNA nuclear transport, regulates gene transcription and translation, and regulates the proliferation, migration, invasion, aging, and other phenotypes of tumor cells. HNRNPAB is closely related to the poor prognosis of cancer patients. In addition, HNRNPAB is also involved in regulating the infection process of influenza virus. It has been simply reported that the relevance of HNRNPAB as a prognostic value in BC. RIP assay was performed by using anti-HNRNPAB antibody (ab199724, Abcam, Cambridge, UK) and according to the manufacturer’s protocol of the EZ-Magna RIP™ Kit (17-701, Millipore, Darmstadt, Germany). Finally, RNA was purified after proteinase K digestion and extracted using TRIzol reagent (GK20008, GlpBio, California, USA). Then we sent the RIP experiment's input group and the anti-HNRNPAB antibody enrichment group to Aksomics (KangChen Bio-tech, Shanghai, China) for RIP-seq.